Genetically engineered mouse model

Show results for

Unknown (880)
Genomics (554)
Transcriptomics (358)
Proteomics (26)
Other (22)
Methylation profiling (9)
Metabolomics (5)

Organisms

Mus musculus (381)
Homo sapiens (85)
Allexis (20)
Arabidopsis thaliana (20)
Callinectes sapidus (20)
Danio rerio (20)
Drosophila (20)
Drosophila melanogaster (20)
Ensifer adhaerens (20)
Entamoeba histolytica (20)
Entamoeba histolytica HM-1:IMSS-A (20)
Escherichia coli (20)
Leishmania major strain Friedlin (20)
Listeria monocytogenes (20)
Medicago truncatula (20)
Methylohalobius crimeensis 10Ki (20)
Mus musculus (20)
Mycobacterium tuberculosis (20)
Oryza sativa Indica Group (20)
Physcomitrium patens (20)
Pseudomonas fluorescens WH6 (20)
Pseudomonas putida KT2440 (20)
Rattus norvegicus (20)
Arabidopsis thaliana (2)
mouse gut metagenome (2)
Callithrix jacchus (2)
Rattus norvegicus (2)
Salmonella enterica subsp. enterica serovar Typhimurium (1)
blank sample (1)
Caenorhabditis elegans (1)

Organisms

Mus musculus (350)
Homo sapiens (43)
Callithrix jacchus (2)
Rattus norvegicus (2)
Salmonella enterica subsp. enterica serovar Typhimurium (1)
Mus musculus musculus (1)
Salmonella enterica subsp. enterica (1)
mouse metagenome (1)
Francisella tularensis subsp. tularensis (1)

Repository

ENA (492)
geo (345)
biostudies-arrayexpress (102)
pride (20)
MassIVE (4)
MetaboLights (4)
EGA (3)
ExpressionAtlas (1)
GNPS (1)
iProX (1)
PanoramaPublic (1)

Tissue

Pancreas (3)
Brain (2)
Cell culture (2)
Lung (2)
Blood cell (1)
Blood platelet (1)
Epithelial cell (1)
Fibroblast (1)
Microglial cell (1)
Pancreatic adenocarcinoma cell line (1)
Pancreatic ductal carcinoma cell (1)
Pancreatic stellate cell (1)
Primary cell (1)
Saliva (1)
Whole body (1)

Disease

Pancreatic ductal adenocarcinoma (3)
Xenografts with H1299 cell line (1)
Alzheimer's disease (1)
Asbestos-related lung carcinoma (1)
Breast cancer (1)
Congenital disorder of glycosylation (1)
Disease free (1)
Lung adenocarcinoma (1)
Pancreatic cancer (1)
Thrombocytopenia (1)

Technology Type

Mass Spectrometry (20)
Shotgun proteomics (9)
Bottom-up proteomics (5)
Affinity purification coupled with mass spectrometry proteomics (4)
Data-dependent acquisition (4)
Mass spectrometry assay (2)
Mass spectrometry (2)
Illumina HiSeq 2000, ILLUMINA (1)
Data-independent acquisition (1)
Top-down proteomics (1)

Instrument Platform

Illumina HiSeq 2500 (8)
Illumina HiSeq 4000 (5)
Illumina HiSeq 2000 (4)
Illumina NovaSeq 6000 (3)
NextSeq 500 (3)
Q Exactive (3)
D1000 ScreenTape Analysis, Qubit Fluorometer. (1)
4000 QTRAP (1)
Orbitrap Fusion Lumos (1)
QTRAP 5500 (1)
TSQ Vantage (1)
Liquid Chromatography MS - alternating - HILIC (1)
Gas Chromatography MS - positive (1)
Liquid Chromatography MS - positive - reverse-phase (1)
Liquid Chromatography MS - negative - reverse-phase (1)
Liquid Chromatography MS - negative - hilic (1)
Liquid Chromatography MS - positive - hilic (1)

Publication Date

2025 (59)
2026 (56)
2024 (54)
2021 (42)
2015 (35)
2023 (32)
2022 (31)
2019 (29)
2014 (17)
2011 (17)
2018 (16)
2016 (15)
2013 (14)
2020 (13)
2017 (13)
2012 (12)
2009 (8)
2010 (5)
2008 (5)
2007 (3)

CHEBI ID

CHEBI:165235 (1)
CHEBI:132767 (1)
CHEBI:192804 (1)
CHEBI:34856 (1)
CHEBI:173361 (1)
CHEBI:58349 (1)
CHEBI:88843 (1)
CHEBI:89731 (1)
CHEBI:192304 (1)
CHEBI:4969 (1)
CHEBI:6039 (1)
CHEBI:166577 (1)
CHEBI:5445 (1)
CHEBI:19092 (1)
CHEBI:17665 (1)
CHEBI:17587 (1)
CHEBI:28717 (1)
CHEBI:45441 (1)
CHEBI:16070 (1)
CHEBI:17992 (1)
CHEBI:33020 (1)
CHEBI:45713 (1)
CHEBI:4828 (1)
CHEBI:146193 (1)
CHEBI:29019 (1)
CHEBI:16508 (1)
CHEBI:50129 (1)
CHEBI:29009 (1)
CHEBI:16680 (1)
CHEBI:18132 (1)

Metabolite Name

C00049 (1)
Fumarylacetic acid (1)
(4'R£¬6R£¬6'S£¬7S£¬8R)-6'-(2-hydroxypentan-2-yl)-4'£¬8-dimethyldecahydro-5H-spiro[indolizine-6£¬2'-pyran]-7£¬8-diol (1)
Ethyl 3-Methyl-5-Methylpyrrole-2-Carboxylate (1)
Pentetrazol (1)
5-Acetyl-2£¬3-dihydro-1£¬4-thiazine (1)
Guanidinosuccinate (1)
HMDB0000511 (1)
Methyl benzoate (1)
7-hydroxychromen-2-one (1)
ACar 22:6 (1)
N-Acetylgalactosamine 6-sulfate (1)
Alpha-Hydroxyisobutyric acid (1)
2'-Deoxyadenosine (1)
N-Acetyl-a-neuraminic acid (1)
(-)-5-(2-Propenyl)-2-oxazolidinethione (1)
2-Propionyl-2-thiazoline (1)
3-Phenylpropyl acetate (1)
O-propanoyl-carnitine (1)
Resveratrol (1)
Pyruvic acid (1)
Pelargonic acid (1)
D-Fructose (1)
Methyltyrosinate (1)
Tetraethylene glycol (1)
Beta-Alanine (1)
Byssochlamic Acid (1)
L-Gulonolactone (1)
N-Glycolylneuraminic acid (1)
Lumichrome (1)

First Public Date

2024 (73)
2026 (67)
2025 (66)
2021 (53)
2023 (47)
2022 (41)
2019 (31)
2014 (30)
2020 (20)
2018 (19)
2015 (16)
2017 (15)
2016 (12)
2013 (1)
2010 (1)

Classification

bacteria (3)

Study type

Transcription profiling by array (60)
RNA-seq of coding RNA (13)
DNA-seq (6)
ChIP-seq (5)
Comparative genomic hybridization by array (4)
Methylation profiling by high throughput sequencing (3)
Cell line - High-throughput sequencing (2)
RNA-seq of coding RNA from single cells (2)
High-throughput sequencing (1)
Animal - High-throughput sequencing (1)
Genotyping by array (1)
Transcription profiling by RT-PCR (1)
Bisulfite-seq (1)
ATAC-seq (1)
Methylation profiling by array (1)

Release Date

2025 (90)
2015 (86)
2023 (84)
2021 (83)
2020 (80)
2022 (74)
2019 (73)
2024 (64)
2016 (62)
2018 (57)
2017 (47)
2014 (36)
2013 (33)
2011 (23)
2012 (21)
2026 (17)
2008 (16)
2009 (15)
2010 (10)
2007 (5)
2004 (3)
2006 (1)
2005 (1)
2002 (1)

Lab affiliation

Memorial Sloan Kettering Cancer Center (3)
1. Garvan Institute of Medical Research, Cancer Ecosystems Program, and The Kinghorn Cancer Centre, Darlinghurst, Sydney, New South Wales, Australia. 2. School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales (UNSW), Kensington, Sydney, New South Wales, Australia. (1)
Beth Israel Deaconess Medical Center, Harvard Medical School Boston MA 02215 United States (1)
Copenhagen Center for Glycomics (CCG), Department of Cellular and Molecular Medicine, University of Copenhagen (1)
Department of Chemistry, Southern University of Science and Technology, Shenzhen, China (1)
Department of Pediatrics Indiana University School of Medicine Riley Hospital for Children (1)
Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA 02115 (1)
Indiana University School of Medicine (1)
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (1)
Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany (1)
Molecular Oncology Moffitt Cancer Center Tampa, FL, USA (1)
NIH/NIDCR (1)
National Key Laboratory of Medical Molecular Biology & Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (1)
Post Graduate Program in Dentistry, Cruzeiro do Sul University, SãoPaulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil; Department of Oral Biology, School of Dental Medicine, The University of Buffalo, State University of New 17 York, Buffalo, NY, USA (1)
Spanish National Cancer Research Center (CNIO) (1)
The Institute of Cancer Reaserach Moecular and Systems Oncology (1)
Washington University in St Louis (1)
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal. Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, Portugal. P.CCC Porto Comprehensive Cancer Center Raquel Seruca, Portugal. (1)

Previous page
1 / 186
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 186
Next page

Sort by:

Relevance

Page size

Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer [RRBS]

Genetic and epigenetic alterations are essential for the initiation and progression of human cancer. We previously reported that primary human medulloblastomas showed extensive cancer-specific CpG island DNA hypermethylation in critical developmental pathways. To determine whether genetically engine...

ORGANISM(S): Mus musculus

2013-10-10 | E-GEOD-45341 | biostudies-arrayexpress

Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer [Methylation profiling by array]

ORGANISM(S): Homo sapiens

2013-10-10 | E-GEOD-45240 | biostudies-arrayexpress

scRNA-Seq of genetically engineered mouse model of Epithelioid Hemangioendothelioma tumors

PRJNA707020 | ENA

RNA sequencing of genetically engineered mouse model lung tumors and normal mouse lung.

PRJNA484951 | ENA

RNA-Seq of genetically engineered mouse model of Epithelioid Hemangioendothelioma tumors

PRJNA707561 | ENA

Modeling melanoma resistance in a genetically engineered mouse model

PRJNA650202 | ENA

A genetically engineered mouse model of NUT carcinoma (CUT&RUN)

PRJNA1008244 | ENA

Transcriptomic Classification of Genetically Engineered Mouse Models of Breast Carcinoma Identifies Human Subtype Counterparts

Background: Human breast cancer is a heterogeneous disease consisting of multiple molecular subtypes. Genetically engineered mouse models (GEMMs) are useful resources for studying breast cancers in vivo under genetically controlled and immune competent conditions. Identifying murine models with cons...

ORGANISM(S): Mus musculus

2013-11-04 | E-GEOD-42640 | biostudies-arrayexpress

A genetically engineered mouse model of NUT carcinoma

PRJNA1008241 | ENA

Mevalonate pathway antagonist inhibits proliferation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models.

Statins are among the most frequently prescribed drugs because of their efficacy and low toxicity in treating hypercholesterolemia. Recently, statins have been reported to inhibit the proliferative activity of cancer cells, especially those with *TP53* mutations. Since *TP53* mutations occur in ...

ORGANISM(S): Homo sapiens

2015-11-04 | E-GEOD-68986 | biostudies-arrayexpress

Previous page
1 / 186
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 186
Next page

Sort by:

Relevance

Page size

1854 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Classification

Study type

Release Date

Lab affiliation

Tags

OmicsDI is part of the ELIXIR infrastructure

Tweets